{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:08:21Z","timestamp":1791821301586,"version":"4.3.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Suzetrigine (Journavx; VX-548), the first selective NaV1.8 voltage-gated sodium channel inhibitor approved by the FDA on 30 January 2025, represents a novel non-opioid option for moderate-to-severe acute pain. Given its recent market entry and unique peripheral mechanism, comprehensive post-marketing safety surveillance is essential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to identify and characterize adverse event signals associated with suzetrigine in the FDA Adverse Event Reporting System (FAERS) using advanced disproportionality and comparator-referenced empirical Bayes (EB) methods, with external triangulation against published literature and WHO VigiBase data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed FAERS reports through the first 8 months post-approval. Disproportionality metrics (ROR, PRR, IC) were supplemented by a comparator-referenced EB profiling approach that incorporated suzetrigine, acetaminophen, ibuprofen, and background \u201cother drugs,\u201d generating 3,000 posterior draws per preferred term (PT). Signals with EB q05 &amp;gt; 2 and no comparator overlap were classified as suzetrigine-unique. High-priority PTs were triangulated with Phase II\/III trial data, systematic reviews, case reports, and VigiBase report counts (February 2026).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 19 prioritized PTs, 14 were suzetrigine-unique. Dominant clusters included sensory disturbances (paresthesia, burning sensation, skin burning sensation, hypoaesthesia; EB q05 11.43\u201331.16), musculoskeletal events (muscle spasms EB q05 31.15), and cutaneous reactions (pruritus, rash). These signals were mechanistically consistent with peripheral NaV1.8 blockade of nociceptors and pruriceptors. Literature and VigiBase data corroborated neurological\/sensory and musculoskeletal signals; psychiatric signals (euphoric mood, abnormal dreams) lacked external support and were deprioritized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world pharmacovigilance analysis identifies a distinct safety signature for suzetrigine, with neurological and sensory disturbances (e.g., paresthesia, burning sensation, skin burning sensation, hypoaesthesia) emerging as prominent signals not fully characterized in pre-approval trials, whereas musculoskeletal and cutaneous events largely align with labeled reactions. These hypothesis-generating findings highlight the need for focused post-marketing surveillance on neurological\/sensory preferred terms through prospective cohort studies and Phase IV trials to quantify incidence, identify risk factors, and optimize risk-minimization strategies for this promising non-opioid analgesic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1814013","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:14:31Z","timestamp":1781190871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The real-world safety evaluation of the selective NaV1.8 inhibitor suzetrigine: disproportionality analysis and flexible empirical bayes signals from FAERS with external triangulation"],"prefix":"10.3389","volume":"17","author":[{"given":"Kun","family":"Lai","sequence":"first","affiliation":[{"name":"Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Faculty of Medicine and Health Sciences, UCSI University Bandar Springhill Campus, Port Dickson","place":["Negeri Sembilan, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Luo","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenie Sin Sing","family":"Tan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, UCSI University Bandar Springhill Campus, Port Dickson","place":["Negeri Sembilan, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Gaurav","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Health Sciences and Technology, UPES","place":["Dehradun, Uttarakhand, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Zheng","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Key Laboratory of General Surgery, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Keat","family":"Tan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, UCSI University Bandar Springhill Campus, Port Dickson","place":["Negeri Sembilan, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/15360288.2025.2555215","article-title":"Patient-reported paresthesia after administration of suzetrigine: a case report","volume":"39","author":"Adams","year":"2025","journal-title":"J. Pain and Palliat. Care Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"934","DOI":"10.4062\/biomolther.2025.046","article-title":"Transforming pain management: suzetrigine, a novel non-opioid analgesic","volume":"33","author":"AlDoughaim","year":"2025","journal-title":"Biomol. and Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bcp.15178","article-title":"Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium\/glucose cotransporter 2 inhibitors","volume":"89","author":"Alkabbani","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/TCRM.S137144","article-title":"Relevance of the weber effect in contemporary pharmacovigilance of oncology drugs","volume":"13","author":"Arora","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1097\/ALN.0000000000005460","article-title":"Suzetrigine, a nonopioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"key":"B6","first-page":"1","article-title":"Efficacy and safety of suzetrigine for acute postoperative pain: a GRADE assessed systematic review and meta-analysis","volume-title":"J. Pain Palliat. Care Pharmacother","author":"Burhan","year":"2025"},{"key":"B7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.32614\/RJ-2017-073","article-title":"openEBGM: an R implementation of the gamma-poisson shrinker model","volume":"9","author":"Canida","year":"2017","journal-title":"R J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4103\/sja.sja_366_25","article-title":"Suzetrigine (VX-548): bidding goodbye to opioids: the latest oral non-opioid analgesic for acute pain","volume":"19","author":"Chittoria","year":"2025","journal-title":"Saudi J. Anaesth."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s11096-023-01592-y","article-title":"Factors associated with underreporting of adverse drug reactions by patients: a systematic review","volume":"45","author":"Costa","year":"2023","journal-title":"Int. J. Clin. Pharm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain\u2014United states, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/cpt.2460","article-title":"Strengthening standards, transparency, and collaboration to support medicine evaluation: considerations from the open science and methodology initiative","volume":"111","author":"Gatto","year":"2022","journal-title":"Clin. Pharmacol. and Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","article-title":"Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions","volume":"32","author":"Hauben","year":"2009","journal-title":"Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated reporting: the impact of US food and drug Administration-issued alerts on the adverse event reporting system (FAERS)","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s00403-025-04297-6","article-title":"Disproportionality analyses of tapinarof-related adverse events based on the FAERS database","volume":"317","author":"Huang","year":"2025","journal-title":"Archives Dermatological Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40264-025-01560-7","article-title":"An evaluation of duplicate adverse event reports characteristics in the food and drug administration adverse event reporting system","volume":"48","author":"Janiczak","year":"2025","journal-title":"Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV1.8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12874-023-01885-w","article-title":"Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions","volume":"23","author":"Lu","year":"2023","journal-title":"BMC Med. Res. Methodol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e90755","DOI":"10.7759\/cureus.90755","article-title":"Suzetrigine as a novel non-opioid analgesic drug in pain management: a review of clinical evidence and therapeutic perspectives","volume":"17","author":"Mach","year":"2025","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain","volume":"18","author":"McCoun","year":"2025","journal-title":"J. Pain Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/molecules31020358","article-title":"Suzetrigine, a NaV1.8 inhibitor as a novel approach for pain therapy\u2014A medicinal and chemical drug profile","volume":"31","author":"Medhat","year":"2026","journal-title":"Molecules"},{"key":"B21","doi-asserted-by":"publisher","first-page":"18817","DOI":"10.1038\/s41598-023-46275-w","article-title":"Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events","volume":"13","author":"Montes-Grajales","year":"2023","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"9865","DOI":"10.3390\/ijms26209865","article-title":"Beyond opioids: a review of suzetrigine for acute pain management","volume":"26","author":"Pham","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e96054","DOI":"10.7759\/cureus.96054","article-title":"Clinical efficacy and safety profile of suzetrigine: a novel non-opioid analgesic targeting NaV1.8 sodium channel","volume":"17","author":"Rejeev","year":"2025","journal-title":"Cureus"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/bcp.15791","article-title":"Improving the spontaneous reporting of suspected adverse drug reactions: an overview of systematic reviews","volume":"89","author":"Routledge","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e70195","DOI":"10.1002\/sim.70195","article-title":"Flexible empirical Bayesian approaches to pharmacovigilance for simultaneous signal detection and signal strength estimation in spontaneous reporting systems data","volume":"44","author":"Tan","year":"2025","journal-title":"Statistics Med."},{"key":"B28","volume-title":"FDA Adverse Event Reporting System (FAERS) Public Dashboard (Limitations and Use Considerations)","year":"2023"},{"key":"B29","volume-title":"FDA Approves first-of-its-kind Non-opioid Pain Medication","year":""},{"key":"B30","volume-title":"Drug Trials Snapshots: JOURNAVX (Suzetrigine)","year":""},{"key":"B31","volume-title":"FDA Adverse Event Reporting System (FAERS) Public Dashboard: Questions and Answers\/Limitations","year":""},{"key":"B32","volume-title":"FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract (QDE)","year":""},{"key":"B34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jpain.2024.11.005","article-title":"Genetic risk factors for chronic pain: insights from genome-wide association studies and SCN10A variants","volume":"26","author":"Veluchamy","year":"2025","journal-title":"J. Pain"},{"key":"B35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40360-024-00821-y","article-title":"A real-world disproportionality analysis of the U.S. FDA adverse event reporting system (FAERS) events for durvalumab","volume":"25","author":"Zou","year":"2024","journal-title":"BMC Pharmacol. Toxicol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1814013\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:14:32Z","timestamp":1781190872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1814013\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":33,"alternative-id":["10.3389\/fphar.2026.1814013"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1814013","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1814013"}}